Objective: We conducted a case-control study to investigate whether clusterin polymorphism (rs11136000) was associated with late-onset Alzheimer's disease in Chinese Han population.
Methods: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was performed on genotype rs11136000 and APOEε4 in 127 patients with late-onset Alzheimer's disease and 143 control individuals. Previous published data from other Chinese samples was also included for further meta-analysis.
Results: APOEε4 was demonstrated to increase the risk of Alzheimer's disease in Chinese population (odds ratio = 2.35, 95% confidence interval: 1.40-3.96). There is no significant association between clusterin rs11136000 with late-onset sporadic AD in our small cohort. However, meta-analysis revealed significant allele and genotype differences between Alzheimer's disease and controls following a recessive model.
Conclusion: Clusterin (rs11136000) was associated with Alzheimer's disease in Chinese Han population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845609 | PMC |
| http://dx.doi.org/10.1177/1533317511432735 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma pTau181 and amyloid markers predict conversion to dementia in idiopathic REM sleep behaviour disorder.
Brain
January 2025
The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC H3A 2B4, Canada.
Blood-based biomarkers for Alzheimer's disease (AD) pathology have been intensively investigated as markers for AD-related neurodegeneration. Comorbid AD pathology is common in dementia with Lewy bodies (DLB). Accordingly, we hypothesized that plasma biomarkers associated with AD pathology might be useful to predict DLB in a cohort of idiopathic/isolated REM sleep behavior disorder (iRBD), an incipient synucleinopathy.
View Article and Find Full Text PDFAfter Risk-Adjustment Change, Dementia Diagnoses Increased In Medicare Advantage Relative To Traditional Medicare.
Health Aff (Millwood)
January 2025
Julie M. Zissimopoulos University of Southern California.
In 2020, the Centers for Medicare and Medicaid Services reintroduced Alzheimer's disease and related dementias to its risk-adjustment payment model for Medicare Advantage (MA) plans. Using 2017-20 data for 100 percent of community-dwelling beneficiaries enrolled in Medicare, we evaluated how the reintroduction of dementia to the risk-adjustment model affected rates of new (incident) dementia diagnoses among beneficiaries enrolled in MA relative to those enrolled in traditional Medicare. In response to the payment change, annual incident dementia diagnosis rates in MA increased by 11.
View Article and Find Full Text PDFChronic Use of Benzodiazepine in Older Adults and Its Relationship with Dementia: A Systematic Review and Meta-Analysis.
Harv Rev Psychiatry
January 2025
From Universidad del Valle (Drs. Rivas, Hernández, Erazo, Martínez, González, Cortés, Muñoz, and Miranda); Hospital Departamental Psiquiátrico Universitario del Valle (Drs. Rivas, Erazo, and Miranda); Fundación Valle del Lili (Dr. Rivas) Universidad Icesi (Dr. Rivas), Cali, Colombia.
Learning Objective: After participating in this CME activity, the psychiatrist should be better able to:• Explain current understanding of the relationship between chronic benzodiazepine use and dementia.
Background: Chronic use of benzodiazepines (BZ) for managing conditions such as anxiety disorders, depression, sleep disorders, and other chronic diseases is widespread; yet, there is considerable controversy regarding its potential links to dementia risk. This systematic review and meta-analysis aims to clarify this relationship by synthesizing and analyzing the available evidence to provide a clearer understanding of whether prolonged BZ use contributes to developing dementia.
The MIR-NAT MAPT-AS1 does not regulate Tau expression in human neurons.
PLoS One
January 2025
Neuroscience Discovery, Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.
The MAPT gene encodes Tau protein, a member of the large family of microtubule-associated proteins. Tau forms large insoluble aggregates that are toxic to neurons in several neurological disorders, and neurofibrillary Tau tangles represent a key pathological hallmark of Alzheimer's disease (AD) and other tauopathies. Lowering Tau expression levels constitutes a potential treatment for AD but the mechanisms that regulate Tau expression at the transcriptional or translational level are not well understood.
View Article and Find Full Text PDFAmyloid beta (Aβ) fibrillation kinetics and its impact on membrane polarity.
J Bioenerg Biomembr
January 2025
Division of Chemical Engineering, Graduate School of Engineering Science, Osaka University, 1-3 Machikaneyamacho, Toyonaka, Osaka, 560-8531, Japan.
Fibrillation of the amyloid beta (Aβ) peptide has often been associated with neurodegenerative pathologies such as Alzheimer's disease. In this study we examined the influence of several potential compositions of the lipid membrane on Aβ fibrillation by using liposomes as a basic model membrane. Firstly, it was revealed that Aβ fibrillation kinetics were enhanced and had the potential to occur at a faster rate on more fluid membranes compared to solid membranes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!